Metformin is the most widely used type 2 diabetes drug, and is known as a “magic medicine” because of its anti-cancer and anti-aging effects. Now, scientists from the University of Dundee in the UK have recently discovered that metformin can also reverse the thickening of harmful myocardial walls that… Continue Reading Metformin may reduce the risk of heart disease, the first clinical trial results in top journals
Following the announcement on February 12 that the ASK1 inhibitor selonsertib (GS4997) missed the first-order endpoint in its first phase III clinical trial (STELLAR-4), Gilead announced on April 25 that selonsertib was in another STELLAR-3 study. The scheduled clinical endpoint of 48 weeks was not reached. STELLAR-4 study… Continue Reading Gilead NASH new drug selonsertib second phase III clinical failure
A female patient, 53 years old, found “rheumatoid arthritis” for 14 years. She was treated with “painkiller” for a long time. She had chronic stomach and enteritis a few years ago and her diet has been bad. Recently, the body was extremely weak and struggling to walk. The family… Continue Reading Long-term use of painkillers, the consequences may be more serious than you think
Drug: maraviroc Magazine: Cell Highlights: 1) First confirmed that CCR5 gene is associated with stroke rehabilitation 2) HIV drug maraviroc can promote recovery of mice from stroke 3) First reported the function of CCR5 in the human brain Stroke is an acute cerebrovascular disease caused by sudden rupture… Continue Reading Are HIV drugs used for “stroke rehabilitation”? Cell first confirmed that the genes edited by He Jiankui affect the human brain
Azithromycin is a macrolide antibiotic commonly used in outpatient clinics. At present, a clinical use is popular. Azithromycin is orally administered for 3 days and stopped for 4 days. Is this usage correct? I. When can azithromycin be used? Azithromycin against Gram-positive bacteria (Staphylococcus aureus, Group A hemolytic… Continue Reading Azithromycin, eat 3 days and stop for 4 days, is this usage correct?
Cimetidine, also known as Methylene guanidine, is a H2 receptor blocker commonly used in primary clinical practice. It has preventive and protective effects against corrosive gastritis caused by chemical stimulation, and stress gastric ulcer and upper digestion. The bleeding also has obvious curative effect and is therefore widely used… Continue Reading 23 clinical new uses of cimetidine
I. Sulfasalazine Mainly used for inflammatory bowel disease, rheumatoid polyarthritis, hemorrhagic proctitis. 1. Usage and dosage The initial dose is 1~2g per day, divided into 3~4 times orally; in the first few weeks, gradually increase the dose to 3~4g a day, orally 3~4 times; after the symptoms improve, it… Continue Reading The first dose of these drugs must be reduced
On February 19, Intercept announced that olbecholic acid (OCA) has achieved positive results in the mid-phase analysis of the key phase III REGENERATE study of patients with nonalcoholic steatohepatitis (NASH) with grade 2 to 3 liver fibrosis. Efficacy data from the primary endpoint showed: 1) At the 18th month… Continue Reading NASH’s new drug wins its first phase III clinical victory, and Abecholic acid is about to open a $40 billion market
Insulin is one of the most important drugs in the history of pharmaceuticals. Since the separation of active insulin from animals by the Canadian doctor Frederick Grant Banting, it has been around for nearly a hundred years and has been continuously upgraded to meet the demand for diabetes. To… Continue Reading After OI388GT terminated the trial, Novo Nordisk deployed oral insulin again, and plans to enter the human clinical clinic within three years.
Gilead Science announced on February 12 that NASH’s research drug, ASK1 inhibitor selonsertib (GS4997), missed the primary endpoint in its first phase III clinical trial (STELLAR-4). STELLAR-4 is a phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of the NASH new drug selonsertib in patients… Continue Reading Gilead NASH new drug selonsertib first phase III clinical failure